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ORIGINAL ARTICLE
Smoking is associated with severity of liver fibrosis but not with histological
severity in nonalcoholic fatty liver disease. Results from a cross-sectional study
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Chris J J Mulderb, Eric T T L Tjwaa and Erwin J M van Geenena
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Gastroenterology and Hepatology, VU University Medical Center, Amsterdam, the Netherlands; cDepartment of Internal Medicine, VU
University Medical Center, Amsterdam, the Netherlands; dDepartment of Pathology, VU University Medical Center, Amsterdam, the
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ABSTRACT
Objectives: To assess the influence of smoking on histological disease severity and fibrosis in real-
world NAFLD patients.
Material and methods: Consecutive NAFLD patients were identified with liver biopsies performed
between 2008 and 2015. Characteristics such as smoking status and total number of pack years were
collected. Biopsies were revised and BRUNT fibrosis and NAFLD activity score (NAS) determined.
Patients with a high NAS (5) were compared to patients with a low NAS (<5) and with advanced
fibrosis (stage 3–4) to patients with no-early fibrosis (stage 0–2). Patients with a history of smoking
(current or past smoker) were defined ever smokers.
Results: Fifty-six patients were included (mean age 49±14.3, 68.9% males and 39.3% history of smok-
ing). Ever smokers had a higher fibrosis score than never smokers; two (IQR 0–3) versus one (IQR
1–1.5) (p¼ .040). Patients with advanced fibrosis smoked significantly more pack years than patients
with no-early fibrosis; 10.6 (IQR 0–25.8) versus 0 (IQR 0–7) (p¼ .011). There is a weak to moderate cor-
relation between fibrosis stage and number of pack years (Spearman’s Rho¼ 0.341, p¼ .012). There
was no difference in NAS between never and ever smokers; 2.8 ± 1.5 versus 3.3± 1.4 (p¼ .205). Patients
with NAS <5 had a median number of pack years of 0 (IQR 0–9) versus a median of 10.3 pack years
(IQR 0–24) in patients with NAS 5 (p¼ .127).
Conclusion: Smoking is associated with severity of NAFLD-related liver fibrosis but not with histo-
logical disease severity. This supports the recommendation to cease smoking for NAFLD patients.
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Nonalcoholic fatty liver disease (NAFLD) is the most expanding
cause of chronic liver disease. NAFLD consists of a spectrum
of conditions, ranging from simple steatosis to nonalcoholic
steatohepatitis (NASH) and ultimately end-stage liver cirrhosis
[1]. The diagnosis of NASH is defined by the presence and pat-
tern of specific histological abnormalities on liver biopsy, such
as inflammation. For this, a system of scoring the individual
features of NAFLD, the NAFLD Activity Score (NAS) was devel-
oped [2]. This score is based on three histological parameters,
namely lobular inflammation, macroscopic steatosis and bal-
looning of hepatocytes.
Advanced stages of NAFLD have been associated with risk
factors such as diabetes, obesity and increasing age [3–5].
Whether smoking aggrevates chronic liver diseases and espe-
cially NAFLD has been increasingly subject of research debate.
In obese rats, smoking increased the histological severity
of NAFLD, favoring the development of NASH by aggrevation
of lobular inflammation and hepatocellular ballooning [6].
The underlying mechanisms seem to be induction of hepato-
cellular apoptosis, oxidative stress and modulation of several
signaling pathways, such as ERK phosphorylation and AKT
activation. The effect of smoking on fibrosis was less clear in
this study. There was upregulation of several fibrogenic
genes (pro-collagen a-2 and TIMP-1), but no significant fibro-
sis deposition in the animals.
In human NAFLD, smoking seems to be associated with
severe fibrosis, as shown in a large cohort study encompass-
ing 1091 patients, collected from enrollment in several studies
[7]. Long-term smoking was significantly associated with the
presence of advanced fibrosis, suggesting cigarette smoking
may accelerate disease progression. However, in this study,
the association between smoking, NASH and the histological
severity of independent NAS components was not extensively
studied. In a brief report by Yilmaz et al, no association was
observed between smoking and severity of NAFLD [8].
Since human results are conflicting and experimental data
suggest smoking can lead to progression from simple NAFLD
to NASH, we conducted the present human cohort study.
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We aim to investigate whether there is an association between
smoking and the presence of NASH, including the individual
histological disease components; lobular inflammation, hepato-
cellular ballooning, steatosis and severity of fibrosis.
Methods
Patient population
All liver pathology reports from 2008 to 2009 in the VU
University Medical Center and from 2010 to 2015 in the
Radboud university medical center were screened for inclu-
sion, if the words NAFLD, NASH or steatosis were mentioned
in the report. Patient details were included when the diagno-
sis nonalcoholic fatty liver disease or nonalcoholic steatohe-
patitis was made on clinical and histological grounds.
Patients were excluded when there was concomitant liver
disease. Patient characteristics such as age, sex, length,
weight, body mass index (BMI), the presence of diabetes mel-
litus type 2 (DM) and alcohol use (units/week) were assessed.
This study was approved by the Institutional Review Boards
of both hospitals.
Liver histology
All biopsies were stained with hematoxylin–eosin and
assessed for fibrosis using Masson’s Trichome or Elastin-Von
Gieson. In each center, the included biopsies were revised by
a single liver pathologist, blinded for clinical information.
Quality of biopsies was assessed and biopsies not meeting
the following requirements were excluded: 20–25mm long
and/or containing more than 11 portal tracts. The stage of
fibrosis was scored with the histological scoring system for
NAFLD developed by Brunt et al [2]. No or early fibrosis was
defined as stage 1 or 2 and advanced fibrosis was defined as
stages 3 or 4. The NAFLD Activity Score (NAS) was used to
assess the severity of histological disease activity, with a total
score between 0–8 based on individual scores for the three
components; steatosis (0–3), lobular inflammation (0–3) and
hepatocellular ballooning (0–2). A NAS of five or higher is
defined as histological steatohepatitis [9].
Smoking history
Smoking history was obtained from chart review and when
unclear from direct interview with patients. Patients were
informed with a study information letter and afterwards tele-
phoned for an interview. From the data obtained from this
interview and medical records, the total number of pack
years smoked by each patient was calculated (one pack year
equals one pack of cigarettes each day during one year).
Patients were furthermore classified as ‘never smokers’ or
‘ever smokers’, the latter in case of current smoking or a his-
tory of smoking.
Statistical analysis
Continuous data are presented with mean and standard devi-
ation (±SD), nominal data as counts (n), percentages and
ordinal data with medians and interquartile ranges (IQR).
Independent t-test or nonparametric tests where applicable
were used to compare continuous variables. Chi-square test
was used to compare categorical variables and
Mann–Whitney U-test for ordinal variables. Correlations were
tested with Pearson’s correlation coefficient or Spearman’s
rho, depending on the level of measurement. A two-sided
level of p<.05 was considered statistically significant. All stat-
istical analyses were carried out using SPSS software (version
22; SPSS Inc., Chicago, IL).
Results
Patient characteristics
A total of 160 pathology reports with the words NAFLD,
NASH or steatosis in the report were screened. Of these 76
were excluded because of a different or concomitant disease.
Of 27 more patients, no sufficient smoking data were pre-
sent. Finally, four biopsies were excluded because of bad
quality. Leading to a total of 56 patients included in the ana-
lysis, with a mean age of 49 ± 14.3 years and 68.9% males. Of
all patients, 22 (39.3%) had a history of smoking (named
hereafter ever smokers). This group comprised of six subjects
(27.3%) who still actively smoke and 16 subjects (72.7%) who
ceased smoking. Mean number of pack years among ever
smokers was 16.3 ± 10.8. Never smokers were significantly
younger than ever smokers (p .028), but BMI, the presence of
DM and alcohol use was not different between groups
(Table 1, near here). There was no correlation between age
and the number of pack years smoked by ever smokers
(Pearson’s R¼ 0.169, p¼ .028).
Liver histology
The median fibrosis score according to Brunt was signifi-
cantly higher in ever smokers than in never smokers; 2
(IQR 0-3) versus 1 (IQR 1–1.5) (p¼ .040). Whereas most
never smokers had no or early fibrosis, subjects who ever
smoked had predominantly early to advanced fibrosis. This
was however not significant. There was no difference in
the NAS between never and ever smokers (p¼ .205)
(Table 1).
Number of pack years and severity of fibrosis
Overall, patients with advanced fibrosis smoked significantly
more pack years than patients with no-early fibrosis; 10.6
(IQR 0–25.8) versus 0 (IQR 0–7) (p¼ .011) (Figure 1(A)). This
observation was not altered after exclusion of never smokers:
patients with advanced fibrosis smoked 22.3 ± 11 pack years,
whereas patients with no-early fibrosis smoked 13± 9.4 pack
years (p¼ .048) (Figure 1(B)). There is a weak to moderate
correlation between the stage of fibrosis and the number of
pack years smoked by all included patients (Spearman’s
rho¼ 0.341, p¼ .012) and a similar trend for ever smokers
(Spearman’s rho ¼ 0.416, p¼ .061).
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Possible confounders in advanced fibrosis
The mean NAS was higher in patients with advanced fibrosis
compared to no-early fibrosis; 3.9 ± 1 versus 2.7 ± 1.5
(p¼ .003). In detail, a higher, but not significant, proportion
of patients with advanced fibrosis had a NAS of 5 or higher
compared to patients with no-early fibrosis (30.8% vs. 9.3%;
p¼ .074). Patients with advanced fibrosis were older (mean
age 60.4 ± 9.7 years vs. 45.5 ± 13.7 years; p< .001).
No other clinical features, such as sex, BMI, type-2DM or
alcohol use differed between patients with no-early fibrosis
compared to advanced fibrosis (data not shown).
Number of pack years and histological disease severity
Overall, patients with NAS <5 compared to patients with
NAS 5 had a median number of pack years of, respectively,
0 (IQR 0–9) versus 10.3 (IQR 0–24) (p¼ .127) (Figure 2(A)).
There were no differences in clinical features, including age,
sex, BMI, the presence of DM and alcohol use between both
groups (data not shown). Also after exclusion of never smok-
ers, no statistical difference could be observed in number of
pack years (NAS <5; 15.3 ± 10.6 vs. 19.9 ± 11.7 in NAS 5;
p¼ .411) (Figure 2(B)). There was no correlation between
number of pack years and NAS in ever smokers (Pearson’s
R ¼ 0.072, p¼ .752).
Discussion
Smoking and fatty liver disease place a heavy burden on
health care systems worldwide. This study addresses the pos-
sible synergistic effect of smoking on histological outcomes
of nonalcoholic fatty liver disease.
We demonstrate in this study that NAFLD patients with
advanced fibrosis smoked more pack years than patients
with no or early fibrosis. These results corroborate the associ-
ation between smoking and severity of NAFLD fibrosis as pre-
viously shown [7]. In a smaller study, no association between
smoking and severity of fibrosis in NAFLD patients was
observed, which may be the result of patient numbers,
comorbidity and selection [8].
The underlying pathomechanisms of our observed associ-
ation cannot be clarified with our cross-sectional cohort
study design. We can only speculate through which mecha-
nisms smoking aggravates fibrosis in NAFLD, based on previ-
ous experimental research.
Figure 1. Number of pack years compared between patients with no-early (stage 0–2) and advanced fibrosis (stage 3–4). Panel A shows the difference in number
of pack years (represented with boxplots with median, IQR and min–max value) for the whole cohort. Panel B shows the difference in number of pack years
(represented as meanþ standard error of the mean) for ever smokers (active and past smokers).
Table 1. Patient characteristics.
Never smokers (n¼ 34) Ever smokers (n¼ 22) p value
Clinical features
Male 24 (70.6%) 14 (63.6%) .586
Age 45.7 (±14.4) 54.2 (±12.9) .028
BMIa 31.2 (±5.6) 29.9 (±6.3) .258
Obese (BMI >30)a 13 (54.2%) 5 (35.7%) .272
Type-2 DMa 7 (21.9%) 8 (40.0%) .160
Alcohol use (units/week)b 0 (IQR 0–7) 7 (IQR 0–14) .111
Histology
Fibrosis score according to Brunt 1 (IQR 1–1.5) 2 (IQR 0–3) .040
No fibrosis (stage 0) 14 (41.2%) 6 (27.3%) .099
Early fibrosis (stage 1–2) 15 (44.1%) 8 (36.3%) .099
Advanced fibrosis (stage 3–4) 5 (14.7%) 8 (36.3%) .099
NAFLD activity score (NAS) (0–8) 2.8 ± 1.5 3.3 ± 1.4 .205
Legend: Expressed as number and percentage for categorical variables, median (IQR) for ordinal variables and mean
(±SD) for continuous variables.
aBMI, Obese n¼ 38, Type-2 DM n¼ 52.
bMedian (IQR) is shown for alcohol use because of non-normal distribution and tested with a Mann–Whitney U-test.
Bold values are significant p-values (<0.05).
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First, the presence of inflammation as a risk factor for pro-
gression to fibrosis in NAFLD has been widely shown [10].
However, we did not find an association between smoking
and NASH or severity of inflammation, ballooning and stea-
tosis. An increasing number of pack years was not correlated
with a higher NAFLD activity score (NAS). The NAS did not
differ between never and ever smokers. Similar results were
seen in other studies [7,8].
The heterogeneity of NAFLD could be a possible reason
for this, with many environmental and genetic factors influ-
encing disease course [11]. These factors could have been
present in our study cohort and are impossible to correct for.
Furthermore, our cohort contained only a small percentage
(14%) of patients with active steatohepatitis and could there-
fore be underpowered to show a possible association
between smoking and histological disease severity.
Second, also a direct effect on fibrogenesis from smoking
could be postulated as an underlying mechanism. NAFLD is a
heterogeneous disease and probably progression is caused
by a multi-hit model [12]. Smoking probably can interfere in
several pro-inflammatory and pro-fibrotic pathways in experi-
mental NAFLD. Chronic hypoxia, as a consequence of smok-
ing, not only led to more hepatic inflammation but also an
increase of pro-fibrotic cytokines [13,14]. Other pathways
involved in fibrogenesis, such as more profound lipid accu-
mulation, oxidative stress and insulin resistance, have been
shown [15]. Stimulation of the nicotinic acetylcholine recep-
tors in hepatic stellate cells by nicotine in vitro suggests a
direct effect of smoking on fibrogenesis [16].
In addition, in other chronic liver diseases such as hepa-
titis C and primary biliary cholangitis, associations between
smoking and fibrosis have been described [17–22].
It is furthermore suggested that smoking increases pro-
gression of fibrosis in other organ systems, including the
pancreas, kidneys, lungs and heart [23–26].
In our study, patients with advanced fibrosis were older
than those with early fibrosis but the number of pack years
was not correlated with the age of patients. Therefore, age
seems to play a minor role in the association between smok-
ing and fibrosis severity. Nonetheless, it endorses the advice
to cease smoking for all patients, irrespective of their bio-
logical age.
The retrospective set-up of a small cohort is a major limi-
tation. With extensive chart review and direct questioning of
patients on smoking history, we aimed to characterize the
cohort as good as possible. However, smoking data were not
validated by direct measurement of serum nicotine concen-
trations, so the possibility of bias by patients is present.
In conclusion, in this study, the number of pack years is
associated with severity of liver fibrosis but not with histo-
logical disease severity in patients with NAFLD. The observed
data may serve as pilot for larger cohorts. These findings still
emphasize the recommendation to cease smoking for all
patients with NAFLD.
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